Daewoong Pharma (069620) — Cash Flow Quality Index
Daewoong Pharma (069620) has a Cash Flow Quality Index of 1.34x as of September 2025. Operating cash flow of ₩57.53 Billion exceeds net income of ₩43.09 Billion, indicating high earnings quality where cash backs reported profits. Explore Daewoong Pharma (069620) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daewoong Pharma Cash Flow Quality Index (2007–2024)
Historical Cash Flow Quality Index for Daewoong Pharma across 15 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 069620 cash generation efficiency.
Annual Cash Flow Quality Index for Daewoong Pharma (2007–2024)
Year-by-year earnings quality comparison for Daewoong Pharma.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.38x | ₩51.49 Billion | ₩21.61 Billion | ▲ +114.7% |
| 2023 | 1.11x | ₩132.57 Billion | ₩119.45 Billion | ▼ -28.5% |
| 2022 | 1.55x | ₩118.21 Billion | ₩76.14 Billion | ▲ +57.2% |
| 2021 | 0.99x | ₩39.99 Billion | ₩40.48 Billion | ▼ -96.9% |
| 2020 | 32.17x | ₩100.98 Billion | ₩3.14 Billion | ▲ +1129.1% |
| 2019 | 2.62x | ₩57.60 Billion | ₩22.01 Billion | ▼ -20.5% |
| 2017 | 3.29x | ₩103.94 Billion | ₩31.58 Billion | ▲ +477.2% |
| 2016 | 0.57x | ₩15.38 Billion | ₩26.97 Billion | ▼ -31.8% |
| 2015 | 0.84x | ₩35.89 Billion | ₩42.93 Billion | ▲ +1.6% |
| 2014 | 0.82x | ₩25.95 Billion | ₩31.54 Billion | ▼ -11.3% |
| 2013 | 0.93x | ₩54.16 Billion | ₩58.40 Billion | ▼ -29.8% |
| 2012 | 1.32x | ₩45.02 Billion | ₩34.08 Billion | ▼ -15.9% |
| 2011 | 1.57x | ₩78.82 Billion | ₩50.19 Billion | ▲ +65.1% |
| 2008 | 0.95x | ₩31.33 Billion | ₩32.93 Billion | ▲ +117.3% |
| 2007 | 0.44x | ₩25.81 Billion | ₩58.95 Billion | — |